News

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain...

A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks...

Roche announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint. After 24 weeks of treatment, RA patients who received...

Novartis has commenced shipment of Fluvirin influenza vaccine for the 2012-2013 influenza season, in the US. Novartis plans to ship more than 30 million doses of the Fluvirin vaccine which has been reformulated to include two...

GlaxoSmithKline, Ligand Pharmaceuticals' partner, has gained FDA priority review status for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus infection. Eltrombopag, known by the...

Catalent has started supplying its antipsychotic drug, Abilify, an orally disintegrating tablet (ODT) to Otsuka Pharmaceutical. Abilify ODT, which utilizes Catalent's Zydis fast dissolve drug delivery technology, is designed to improve manic symptoms associated...

A compound that mops up debris of damaged cells from the bloodstream may be the first in a new class of drugs designed to address one of medicine's most difficult challenges - stopping the formation of blood clots...